2.380EUR-0.42%Mkt Cap: 108.50M EURP/E: —Last update: 2026-05-19
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for …
Industry Peers
Medical Instruments & Supplies93.26BDKKP/E 44.3
80.55BEURP/E 35.2
25.95BCHFP/E 40.6
18.23BSEKP/E 32.2
17.18BSEKP/E 94.2
16.56BEURP/E 61.9
16.24BEURP/E 100.1
14.24BCHFP/E 40.0
loading…
Indicators:|
Key Statistics
Company
Market Cap108.50M EUR
Enterprise Value114.71M EUR
Revenue (TTM)15.33M EUR
Gross Profit6.33M EUR
Net Income (TTM)-90.08M EUR
Revenue/Share0.3880 EUR
Last Price2.380 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees153
CountryBE
SectorHealth Care
IndustryMedical Instruments & Supplies
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.60
PEG—
EV/EBITDA-1.41
EV/Revenue7.48
P/S6.89
P/B2.92
EPS (TTM)-2.14
EPS (Forward)-1.51
52W Range
2.3500% of range8.870
52W High8.870 EUR
52W Low2.350 EUR
Profitability
Gross Margin63.13%
Oper. Margin-321.72%
EBITDA Margin0.00%
Profit Margin-899.05%
ROE-183.36%
ROA-76.04%
Growth
Revenue Growth498.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-68.98M EUR
CapEx (TTM)3.77M EUR
FCF Margin-284.10%
FCF Yield-40.13%
Net Debt10.15M EUR
Net Debt/EBITDA-0.12
Balance Sheet
Debt/Equity0.82
Current Ratio0.99
Quick Ratio0.86
Book Value/Sh0.8300 EUR
Cash/Share0.6000 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 EUR
Target Range3.500 EUR – 13.00 EUR
# Analysts3
Ownership
Shares Out.43.66M
Float24.24M
Insiders36.18%
Institutions21.36%
Technical
SMA 502.670 (-10.8%)
SMA 2003.975 (-40.1%)
Beta—
S&P 52W Chg27.23%
Avg Vol (30d)96.47K
Avg Vol (10d)123.32K
Technical Indicators
RSI (14)38.6
MACD-0.0642
MACD Signal-0.0547
MACD Hist.-0.0095
BB Upper2.878 EUR
BB Middle2.630 EUR
BB Lower2.381 EUR
BB Width18.90%
ATR (14)0.1829 EUR
Vol Ratio (20d)0.92x